Ovarian Cancer and Us - best viewed in FIREFOX

Search: this blog, links from posts and the web.....

Loading...

Wednesday, May 13, 2009

The role of genetic assessment in determining a patient's disease risk - JAAPA: Official Journal of the American Academy of Physician Assistants



The role of genetic assessment in determining a patient's disease risk - JAAPA: Official Journal of the American Academy of Physician Assistants

Management of extracolonic tumours in patients with Lynch syndrome : The Lancet Oncology



Management of extracolonic tumours in patients with Lynch syndrome : The Lancet Oncology

Blog: Genetic Tests and Breast Cancer Risk: Not Perfect ACS - MLPA not available in U.S. (2006)




Blog of Rights: Official Blog of the American Civil Liberties Union Who Owns Your Genes?



Blog of Rights: Official Blog of the American Civil Liberties Union Who Owns Your Genes?

Advanced Cancer of the Ovary: Intraperitoneal Chemotherapy as a New Therapeutical Option — In Vivo



Advanced Cancer of the Ovary: Intraperitoneal Chemotherapy as a New Therapeutical Option — In Vivo

The temporal stability of the Symptom Index among women at high-risk for ovarian cancer.



The temporal stability of the Symptom Index among women at high-risk for ovarian cancer.
Kimberly A Lowe, M Robyn Andersen, Nicole Urban, Pamela Paley, Charles W Dresher, and Barbara A Goff
Gynecol Oncol, May 6, 2009;






Molecular Diagnostics Program, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA; Exponent Health Sciences, Seattle, Washington, USA.


OBJECTIVE: To evaluate the temporal stability of self-reported symptoms known to be associated with ovarian cancer. METHODS: This report is a longitudinal analysis of symptom reporting from 123 women who participated in the Seattle-based Ovarian Cancer Early Detection Study (OCEDS). The OCEDS population includes women at increased risk of ovarian cancer based on a family history of cancer or a BRCA I/II mutation. Data on symptoms were collected at two time points using a Symptoms Index that included abdominal pain, pelvic pain, feeling full quickly, inability to eat normally, abdominal bloating, and increased abdominal size. RESULTS: There was a median of 101 days between the two time points, with a range of 72-332 days. The median age of the women was 51, with a range of 32-79 years. Abdominal bloating was the most commonly reported symptom at both time points. The symptom least commonly reported at the two time points was inability to eat normally. The Symptoms Index was negative at both time points for 86% of all women and positive at both time points for 2% of all women. There were no statistically significant patterns of change for symptom reporting between time points. CONCLUSIONS: The Symptoms Index and women's report of abdominal pain, pelvic pain, feeling full quickly, unable to eat normally, abdominal bloating, increased abdominal size were stable between two time points in this sample. These findings provide evidence that longitudinal measurements of symptoms reporting by women in a screening study are likely to be reliable.

PMID: 19427026

Venous thromboembolism in recurrent ovarian cancer-patients:




Influence of Ovarian Cancer Risk Status on the Diagnostic Performance of the Serum Biomarkers Mesothelin, HE4, and CA125 -- Shah et al. 18 (5): 1365 -- Cancer Epidemiology Biomarkers & Prevention



Influence of Ovarian Cancer Risk Status on the Diagnostic Performance of the Serum Biomarkers Mesothelin, HE4, and CA125 -- Shah et al. 18 (5): 1365 -- Cancer Epidemiology Biomarkers & Prevention

Relationship between Epidemiologic Risk Factors and Hormone Receptor Expression in Ovarian Cancer: Results from the Nurses' Health Study -- Hecht et al. 18 (5): 1624 -- Cancer Epidemiology Biomarkers & Prevention



Relationship between Epidemiologic Risk Factors and Hormone Receptor Expression in Ovarian Cancer: Results from the Nurses' Health Study -- Hecht et al. 18 (5): 1624 -- Cancer Epidemiology Biomarkers & Prevention

ACLU sues over patents on breast cancer genes - CNN.com



ACLU sues over patents on breast cancer genes - CNN.com